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ABSTRACT: Morphologic, immunologic, and cytogenetic features were studied in 30 newly diagnosed 
patients with CD34-positive (CD34 +) de nova acute myeloid leukemia (AML) in comparison with 30 pa- 
tients with CD34-negative (CD34 -) AML. Karyotype at diagnosis was abnormal in 25/30 CD34 + AML pa- 
tients, of which nine had major karyotype aberrations (MAKA). Clonol chromosome changes were de- 
tected in 9/30 patients with CD34 - AML. The most frequent chromosome aberration in CD34 + patients 
was -5/5q - ,  an aberration showing a strong association with the M2 FAB subtype of AML. Other recur- 
ring chromosome changes involved chromosome 16q (four cases) and chromosome 17p (three cases). Total 
or partial monosomy 7q was detected in three cases. Among CD34 - AML, two patients had the classical 
t(15;17) and two had structural aberrations of 6q. Among patients with CD34 + AML, nine had MAKA 
in association with trilineage myelodysplasia (TMDS). TMDS was infrequent in CD34 + AML w/thout MAKA 
and in CD34- AML. Complete remission (CR) was achieved in 8/30 CD34+ AML (26%), as compared 
with 22/30 CD34- AML (73%), and median survival was 2 months in the former group and 8 months 
in the latter. No patient with CD34 + AML and MAKA achieved CR, whereas 8/21 CD34 + AML without 
complex chromosome changes or with normal karyotype achieved CR. 
In conclusion, a distinct cytogenetic profile may be associated with CD34 + AML. Cytogenetic findings 
in CD34 + AML may be clinically relevant in that they may disclose a subset of patients with MAKA with 
a low CR rate. 
INTRODUCTION 
The CD34 monoclonal ntibody detects a 110-115 kD mem- 
brane glycopmtein present on 1-2 % of normal bone marrow 
cells, including unipotent and multipotent progenitors [1, 
2]. CD34 expression ishigher on early progenitor cells and 
tends to decrease progressively with maturation [3]. 
In order to better understand the clinico-biologic sig- 
nificance of CD34 positivity in acute leukemia, growing at- 
tention has been devoted over the last 5 years to the presence 
of CD34 + blast cells in acute myeloid leukemia (AML), high- 
lighting some important cytogenetic and clinical correlations 
in this immunologic subset of AML [4-6]. 
This stage-specific marker was found in 40-50% of AML 
cases, possibly identifying a subset of patients with a low 
remission induction rate. Patients with CD34 + AML have 
been frequently shown to fall within the M1-M2 category of 
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the FAB classification and to carry clonal abnormalities in- 
volving the long arm of chromosome 7 [4, 5]. 
To further analyze the cytogenetic and clinicopathologic 
features of CD34 + AML, we performed morphologic, im- 
munologic, and cytogenetic (MIC) studies in 60 newly diag- 
nosed adult AML patients, 30 of whom expressed the CD34 
antigen in more than 20% blast cells. 
PATIENTS AND METHODS 
Sixty patients with de nova AML, seen at our Institution be- 
tween January 1988 and July 1992, are included in the pres- 
ent report. Bone marrow (BM} smears were available for re- 
view in all cases. Immunologic and cytogenetic analysis were 
performed successfully at diagnosis. The patients were 
divided into two groups according to the positivity or nega- 
tivity for the CD34 stem cell marker. 
Cytologic Studies 
Morphology: Patients were classified according to the FAB 
criteria [7]. Bone marrow smears were reviewed to assess the 
presence of myelodysplastic features. According to previously 
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proposed criteria [8, 9], tri l ineage myelodysplasia (TMDS) 
was defined by the presence of more than 25% dysplastic 
erythroblasts and more than 50% abnormal granulocytes and 
megakaryocytes. 
Immunophenotyping: BM cytospin preparations and/or pe- 
ripheral blood smears were stained by an immunocytochem- 
ical method using alkaline phosphatase-anti-alkaline phos- 
phatase (APAAP) complexes [101. To minimize Fc nonspecffic 
binding, the slides were pre-incubated with rabbit serum 
(Dakopatts, Copenhagen, Denmark). Reactivity was tested to 
a panel of monoclonal antibodies purchased from various 
firms: stem cell marker: HPCA-1 (CD34); myeloid-associated 
markers: LeuM1 (CD15) (Becton-Dickinson, Mountain View, 
CA); My9 (CD33), My7 (CD13), My4 (CD14) (Coulter Inc., Hia- 
leah, FL), GplIb/IIIA (CD41a) (Dakopatts, Copenhagen, Den- 
mark); lymphoid-associated markers: Leu12 (CD19) (Becton- 
Dickinson), OKBCalla (CD10), OKT16 (CD7), OKTl l  (CD2) 
(Ortho Diagnostic System Inc., Raritan, NJ). 
Cytogenetic Studies 
Chromosome analysis was performed at initial presentation 
in all patients. BM samples were cultured for 24 and 48 hours 
without mitogens. Synchronization with methotrexate and 
thymidine was performed. Metaphases were G-banded with 
Wright stain [10]. Chromosome aberrations were described 
according to the International System for Human Cytogenetic 
Nomenclature (ISCN) [11]. The presence of three or more 
events of translocation ornon-disjunction i the same clone 
was defined as "major karyotype aberration" (MAKA). Mi- 
nor karyotype aberration (MIKA) was defined by one or two 
such events [12]. 
Clinical Studies 
Salient clinical features at presentation, outcome of remis- 
sion induction therapy, and survival were analyzed in all pa- 
tients. 
RESULTS 
Thirty patients (50%) had more than 20% blast cells express- 
ing the CD34 antigen. Positivity for the anti-CD34 monoclo- 
nal antibody was less than 3% in the blast cells of 30 pa- 
tients, here referred to as CD34-.  
Cytologic Studies 
FAB subtypes in CD34 + and CD34 - are detailed in Table 
1. The M2 FAB subtype was found more frequently among 
CD34 + patients (12/30) than among CD34 - patients [2/30). 
Conversely, the M5 FAB subtype was found in 4/30 CD34 + 
patients versus 11/30 CD34- patients. 
Morphologic abnormalities affecting mult iple cell lin- 
eages, fulfilling the stringent criteria for the diagnosis of AML 
with TMDS, were present in 12 patients with CD34 + AML 
and were not assessable in 10 patients because of an over- 
whelming blast infiltrate. In eight patients with CD34 +, AML 
dysplastic features were present only in the erythroid and/or 
granulocytic series~ 
In patients with CD34- AML, morphologic abnormali- 
ties of the non-blast cell population were mostly confined 
Table 1 Clinical features at presentation, FAB subtypes, 
response to chemotherapy and survival in 
patients with AML CD34 + and CD34 - a 
CD34 + CD34 - 
Age (yr) 64 (24-81) 63 (14-75) 
Hemoglobin value (g/d0 8.6 (5-10.5) 9.2 (5.6-13) 
Leukocyte count ( x 109/L) 8. (1-83) 25. (1-249) 
Platelet count ( × 109/L) 90. (18-488) 80. (26-240) 
FAB subtypes b M1 (3), M2 (12) M1 (2), M2 (2) 
M4 (7), M5 (4), M3 (4), M4 (11) 
M6 (2), M7 (2) M5 (11) 
CR (%) 33 73 
Survival (too) 2 8 
a The results are reported as median value; variation ranges are given in 
parentheses. 
b Number of cases in each FAB category. 
Abbreviations: FAB, French-American-British; AML,acute myeloid leuke- 
mia; CR, complete remission rate. 
to the granulocytic lineage (seven patients), whereas my- 
elodysplasia affecting more than one cell l ineage was seen 
in five patients, none of whom fulfilled the cytologic riteria 
for the diagnosis of AML with TMDS. TMDS was not assess- 
able in 18 patients because of an overwhelming blast infiltrate. 
Immunophenotyping: All cases expressed at least one mye- 
loid-associated antigen (CD33, CD13, CD15, CD14, glycopho- 
rin, and CD41a). 
CD34 expression was negatively correlated with the CD14 
and CD15 positivity, the latter two myelomonocytic antigens 
having been found more frequently in CD34- AML, as 
reported in Figure 1, where immunophenotypic data are 
summarized. 
Unequivocal positivity for the CD41a platelet antigen was 
found in a minority of cells (5-10%) in six patients with 
CD34 + AML and in one patient with CD34- AML. 
Inappropriate expression of lymphoid-associated antigens 
was detected in six patients with CD34 + AML, two of whom 
expressed the CD19 antigen, two the CD10, one the CD2, and 
one the CD7. Positivity for CD7 was found in one patient with 
CD34- AML. 
Cytogenetic Studies 
Results of chromosome investigations are detailed in Tables 
2 and 3. 
Karyotype at diagnosis was abnormal in 25/30 patients 
with CD34 + AML, nine of whom had MAKA. The most fre- 
quent aberrations involved the long arm of chromosome 5.
Total or partial monosomy 5q plus additional aberrations 
were detected in eight patients with AML-M2, whereas one 
patient with AML-M4 had a 5q translocation asthe sole aber- 
ration. In five cases the abnormal 5q chromosome was found 
in the context of complex karyotypes. 
Other recurring chromosome aberrations in this group of 
patients were deletions or translocations of 16q22 (four pa- 
tients), and deletions or translocations of 17p and -7/7q- 
(three patients). Trisomy 11q, del(11)(q13q23), and monos- 
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F igure  1 Percentage of AML cases showing more than  20% posit ivity for immunolog ic  markers (CD34 + cases: 
dark co lumns;  CD34-  cases: dotted co lumns)  (LM: lymphoid-associated markers). 
Tab le  2 C lona l  chromosome aber ra t ions  in  25 pat ients  w i th  CD34 + AML 
Patient Age FAB Modal Abnormal  cells/ 
no. (yr) subtype Karyotype normal  cells 
1 67 M4 46,XX,der(1)add(1)(q32)i(1) (q10)46,idem,i(11){qlO) 8/3 
2 51 M4 45,XX, - 5,der(22)t(22;?)(q11;?) 6/6 
3 61 M4 47,XY, + 8 5/5 
4 54 M2 46,XX,t(5;10)(q12;q26) 8/2 
5 33 M6 49,XY, + 11,der(13)t(13;?)(p11;?), + mar l ,  + mar2/ 9/7 
50, idem, + mar3 
6 26 M2 47,XX,t(8;21)(q22;q22),del(15)(q15) 7/3 
7 40 M6 45,XY, - 8,der(13)t(13;?)(q14;?),del(20)(qllq13) 12/5 
8 24 M1 46,XY,del(3)(q2 lq26),dup[17)(q12q14) 12/4 
9 31 M4 46,XX,t(9;11)(p22;q23) 8/4 
10 55 M2 44,XX,del(5)(q13q33),del(16)(q22),der(17) 
t[17;?)(p12;?), - 18,der(20)t(20;?)(p11;?), 
- 21/45,idem, +mar 
11 71 M2 46,XX, -4,del(5)(q21q32), + 10 , -  14,del(17)(p11), 
+ mar 
12 47 M4 47,XX, + 11 
13 64 M2 46,XX,del(6)(q22)/47,idem, + 22 
14 50 M4 44,XY,der(6)t(6;7)(p23;p14),-  7,der(16)t(11;16) 
(q13;q22), - 19 /45 , idem, ,  mar l  10/0 
15 61 M2 43,XY, - 3, - 5,add(15)(q22), - 17 8/2 
16 72 M2 43,XY, - 5,del(11)(q23),t(12;13;15) 10/0 
(q13;q13;p11),del(16)(q22),der(17)t(17;?) 
(p12;?), - 18, - 21 
17 69 M2 47,XY, + mar(E-size) 10/0 
18 61 M2 45,XY, - 5,i(17q) 7/3 
19 69 M5 46,XY,del(11)(q13q23) 8/4 
20 73 M7 45,XY, - 17 4/6 
21 64 M7 46,XY,del(7)(q22q35)/45,idem, - 9 12/0 
22 69 M4 46,XX,del(16)(q22) 12/6 
23 81 M2 46,XX,del(5)(q21q31) 10/0 
24 68 M2 44,XX,del(5)(q13q31), - 7,del(11)(q13q23), - 12 6/4 
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Table 3 Clonal chromosome aberrations in 10 patients with CD34-  AML 
Patient Age FAB Modal Abnormal cells/ 
no. (yr) subtypes Karyotype normal cells 
1 21 M3 46,XX,t(15;17)(q22;q12) 10/0 
2 14 M3 46,XY,t(15;17)(q22;q12),47,idem, + 22 10/0 
3 25 M1 45,XY,inv(3)(q21q26), - 8/46,inv(3) 9/2 
(q21q26),del(8)(q12) 
4 75 M5 46,XY,der[8)t(8;?)(q22;?) 4/6 
5 36 M5 46,XX,del(6)(q12q14) 6/4 
6 75 M4 47,XY, + 15 8/2 
7 68 M4 46,XY,del(5)(q14q21)/43,idem, - X, 9/1 
-Y , -7  
8 56 M1 46,XX,del(4)(p15) 7/3 
9 60 M4 46,del[6q) 7/3 
Nine of 30 patients with CD34 - AML had chromosome 
aberrations, one of whom had MAKA. In this group, two pa- 
tients with AML-M3 had the t(15;17) and two patients had 
aberrations of the long arm of chromosome 6. Aberrations 
involving the long arm of chromosomes 3 and 5 were de- 
tected in one patient each. 
Clinical Features 
Clinical data at presentation are summarized in Table 1. 
Except for median white blood cell count, no important 
difference merged when comparing clinical features in pa- 
tients with CD34 + AML and those with CD34 - AML. The 
median age, hemoglobin value, and platelet count were simi- 
lar. The M2 and M5 FAB subtypes were more frequently en- 
countered in CD34 + and CD34- patients, respectively. 
All  patients were treated with a standard induction regi- 
men consisting of an anthracycline drug with cytarabine, in 
combination with vindesine, cytarabine and etoposide, when 
the FAB diagnosis was M4 or M5. Eight of 30 patients (27%) 
with CD34 + AML attained complete remission (CR), com- 
pared with 22/30 (73%) with CD34 - AML (p = 0.0003). The 
overall median survival was 2 months in the CD34 + group 
and 8 months in the CD34- AML. 
Cyiogenetic Findings and Clinico-Cytologic Features 
In patients with CD34 + AML, two subgroups of patients ac- 
cording to the presence or absence of MAKA could be iden- 
tified. 
All  nine patients with MAKA had TMDS (nos. 5, 7, 10, 
11, 14, 15, 16, 21, and 24 in Table 2), six of whom had a mi- 
nor megakaryoblastic component (nos. 5, 10, 11, 14, 16, and 
24 in Table 2), as shown by posit ivity for the CD41 platelet 
antigen. 
In patients with MIKA or normal karyotype, TMDS was 
detected in 3/16 cases, none of whom had a minor mega- 
karyoblastic component. 
Inappropriate expression of lymphoid antigens was de- 
tected in six patients (nos. 1, 2, 6, 9, 19, and 22 in Table 2) 
with MIKA or normal karyotype. 
A significant difference in the complete remission rate 
of these two subgroups was detected: none of the patients 
with MAKA attained a CR, whereas 8/21 [31%) patients (nos. 
1, 4, 6, 8, 9, 12, 13, and 25 in Table 2) with MIKA or normal 
karyotype attained CR (p = 0.03). 
DISCUSSION 
Morphologic, immunologic, and cytogenetic studies have 
been shown to be valuable in defining disease subsets of AML 
with distinct clinicopathologic features and prognosis [13-16]. 
This multiparameter study of 60 newly diagnosed AML 
patients treated at a single institution extends previous ob- 
servations on CD34 + AML [4-6], showing that a) CD34 + 
AML has a distinct cytogenetic profile with respect to CD34 - 
AML; b) within CD34 + AML, a subset of patients with dis- 
tinct cytologic and clinical features can be recognized ac- 
cording to the cytogenetic pattern; and c) prognosis in CD34 + 
AML is worse than in CD34- AML. 
Cytogenetic Profile of CD34 + AML 
The frequent occurrence of aberrations involving the long 
arm of chromosome 7 in CD34+ AML was recognized as 
early as 1988 by Vaughan and colleagues [4] and later con- 
firmed by Borowitz et al. [6], who found the -7/7q- abnor- 
mality in 8/26 CD34 + AML as compared with 1/28 CD34 - 
AML. Likewise, Geller et al. [6] frequently detected abnor- 
malities of chromosome 5 and/or 7 in CD34 + AML. In these 
series, however, asignificant fraction of patients with preced- 
ing chemotherapy of another tumor (secondary AML) or with 
a prior history of myelodysplasia was included. 
In this study of de novo AML, the most frequent chromo- 
some abnormality in CD34 + patients was -5 /5q-  (eight 
cases), whereas aberrations ofchromosome 7 were detected 
in three patients. Al l  patients with 5q abnormalities had ad- 
ditional chromosome changes and 5q-  was never found as 
the sole aberration. 
All eight patients with - 5/5q- had features of AML-M2, 
while only four patients with CD34 + AML-M2 did not show 
chromosome 5q abnormalities, thus suggesting that the AML- 
M2/ -5 /5q-  subtype may represent a previously unrecog- 
nized cytologic-cytogenetic association among CD34 + AML. 
Noteworthy is the observation that our patients with AML- 
M2/ -  5/5q- showed a poor prognosis, none of them having 
achieved CR with a survival range of less than 1-15 months 
(median 1 month). 
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Other recurring chromosome aberrations involved the 
long arm of chromosome 16 with a breakpoint at band q22 
and the short arm of chromosome 17 in four and three cases, 
respectively. 
Al l  patients with 16q22 aberrations had mult iple chro- 
mosome changes, frequently tril ineage myelodysplasia, and 
did not show abnormal eosinophils in the BM, suggesting 
that complex karyotypes with aberrations of 16q may be as- 
sociated with a different cytologic picture, compared with 
that of patients carrying the inv(16)(p13q22). This finding is 
in keeping with a previous tudy showing different clinico- 
pathologic features in myeloid neoplasias with 16q deletion 
versus 16q inversion [17]. 
Aberrations of the short arm of chromosome 17 have re- 
cently been added to the list of chromosome changes non- 
randomly associated with secondary leukemia [18], a dis- 
ease subset in which the involvement of chromosomes 5 and 
7, as well as complex chromosome r arrangements, have been 
well documented. 
In this series, aberrations of chromosome 5, 7, 16, and 17 
occurred in the context of complex karyotypes in six cases, 
and were detected as single aberrations in two cases only. 
Thus, some cytogenetic features in CD34 + de novo AML re- 
call those usually found in secondary AML [18-20]. Notewor- 
thy is the fact that 25/30 CD34 + patients in this series had 
been professionally exposed to pesticides and organic sol- 
vents for many years, whereas such exposure was uncom- 
mon (5/30) cases) in CD34- patients [21]. 
Other recurring chromosome changes in CD34 + AML, 
i.e., trisomy 11q and del(11)(q13q23), were previously de- 
scribed in myelodysplasia and preleukemic syndromes [22, 
23]. Most of our CD34 + patients had the features of tril in- 
eage MDS. 
Cytogenetic Patterns and Clinicopathologic Features 
Patients with MAKA (i.e., three or more events of transloca- 
t ion or non-disjunction i the same clone) appear to repre- 
sent a distinct cl inicopathologic entity of CD34 + AML, as 
these patients frequently showed myelodypslastic features 
of the nonblast cell populat ion associated with circulating 
megakaryoblasts. Such cytologic findings were uncommon 
in CD34 + patients with MIKA (one or two aberrant events 
in the abnormal clone) or with normal karyotype. Although 
the reason accounting for this difference is unknown, it is 
reasonable to assume that transformation may have involved 
an early CD34 + progenitor cell both in patients with MAKA 
and in patients with MIKA or normal karyotype and that 
l imited differentiation along multi l ineage pathways may be 
maintained in the former group and abolished in the latter. 
Inappropriate xpression of lymphoid-associated markers 
was only detected in CD34 + patients with MIKA or normal 
karyotype and was not detected in patients with MAKA and 
in CD34- patients. 
Clinical Outcome in CD34 + AML 
Patients with CD34 + AML are less responsive to chemother- 
apy than patients with CD34 - AML, resulting in a signifi- 
cantly lower CR rate and in a shorter overall survival. Notewor- 
thy, all patients in this study were treated with the same 
induction regimen, followed by monthly maintenance che- 
motherapy, over a 2-year period. 
While other cl inical parameters with prognostic predict- 
ability, such as age and WBC count at presentation, could 
not account for this discrepancy, patients with CD34 + AML 
had unfavorable cytogenetic abnormalit ies more frequently 
than patients with CD34 - AML. Furthermore, a particularly 
severe outcome was obtained in CD34 + patients with MAKA, 
the presence of which allowed for the identification ofa sub- 
group of CD34 + AML resistant to induction therapy. This 
finding stresses the prognostic importance of karyotype find- 
ings in AML. 
In conclusion, we have studied the cytogenetic and 
cl inicopathologic features in CD34 + AML, in comparison 
with CD34- AML, showing that a distinct cytogentic pro- 
file may be associated with CD34 + AML. Among CD34 + 
AML, a strong association was found between the M2 FAB 
subtype and chromosome 5q aberrations. Cytogenetic find- 
ings in CD34 + AML may be clinically relevant in distinguish- 
ing CD34 + patients unlikely to achieve CR with a conven- 
tional induction regimen. 
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